Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. CBRS
3. FDX
4. USO
5. SPY
6. MU
7. KBH
8. HTZ
9. HON
10. JPM

Go back to Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010

Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

August 3, 2021 6:00 AM EDT

In NORSE TWO, ONS-5010 achieved statistically significant and clinically relevant primary (p = 0.0052) and key secondary (p = 0.0043) efficacy endpoints with 41% of subjects gaining at least 15 lettersIn NORSE TWO, ONS-5010 was safe and well tolerated Management to host conference call and webcast today at 8:00 a.m. ET

ISELIN, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) --... More